背景:粘膜相关淋巴组织1(MALT1)调节T辅助细胞分化,促炎细胞因子的产生,表皮增生参与银屑病的病理过程。本研究旨在探讨银屑病患者血MALT1水平与治疗结果的相关性。
方法:在210例银屑病患者开始或转用新疗法之前,通过逆转录-定量聚合酶链反应在外周血单核细胞中检测到MALT1,50个疾病对照,和50个健康对照。在银屑病患者的(M)1,M3和M6月评估银屑病面积严重度指数(PASI)评分。
结果:与疾病对照和健康对照相比,银屑病患者的MALT1升高(均p<.001);并且与银屑病患者的体重指数(p=.019)和PASI评分(p<.001)呈正相关。M1、M3和M6的PASI75率为22.9%,46.2%,和71.0%,而M1、M3和M6的PASI90率分别为3.8%,29.0%,50.5%,分别,牛皮癣患者。接受生物制剂的银屑病患者M1、M3和M6的PASI75/90比率与未接受生物制剂的患者相比增加(所有p<0.05)。在M6时达到PASI75(p=.001)和PASI90(p<.001)的银屑病患者中,治疗前的MALT1高于未达到该水平的患者。亚组分析发现,在接受生物制剂的银屑病患者(曲线下面积[AUC]:0.723和0.808)中,治疗前MALT1具有更强的预测PASI75和90实现能力。
结论:血液MALT1测量可能有助于预测银屑病患者的预后,尤其是那些接受生物制剂的人。
BACKGROUND: Mucosa-associated lymphoid tissue 1 (MALT1) modulates T helper cell differentiation, pro-inflammatory cytokine production, and epidermal hyperplasia to participate in the pathology of psoriasis. This study aimed to explore the correlation of blood MALT1 with treatment outcomes in psoriasis patients.
METHODS: MALT1 was detected in peripheral blood mononuclear cells by reverse transcription-quantitative polymerase chain reaction in 210 psoriasis patients before starting or converting to a new therapy, 50 disease controls, and 50 healthy controls. The psoriasis area severity index (PASI) score was evaluated at month (M)1, M3, and M6 in psoriasis patients.
RESULTS: MALT1 was increased in psoriasis patients versus disease controls and healthy controls (both p < .001); and positively related to body mass index (p = .019) and PASI score (p < .001) in psoriasis patients. PASI75 rate at M1, M3, and M6 was 22.9%, 46.2%, and 71.0%, respectively; while PASI90 rate at M1, M3, and M6 was 3.8%, 29.0%, and 50.5%, respectively, in psoriasis patients. PASI75/90 rates at M1, M3, and M6 were increased in psoriasis patients receiving biologics versus those without (all p < .05). Pretreatment MALT1 was higher in psoriasis patients who achieved PASI75 (p = .001) and PASI90 (p < .001) at M6 compared to those who did not achieve that. Subgroup analyses discovered that pretreatment MALT1 had a stronger ability to predict PASI75 and 90 realizations in psoriasis patients receiving biologics (area under the curve [AUC]: 0.723 and 0.808) versus those without (AUC: 0.594 and 0.675).
CONCLUSIONS: Blood MALT1 measurement may assist in predicting outcomes in psoriasis patients, especially in those receiving biologics.